Evaluation of 18F-UCB-H as a novel PET tracer for Synaptic vesicle protein 2A in the Brain

Journal of Nuclear Medicine

Volumn 55, Issue 8, 2014, Pages 1336-1341

  Warnock, Geoffrey I ^a   Aerts, Joël ^a   Bahri, Mohamed Ali ^a   Bretin, Florian ^a   Lemaire, Christian ^a   Giacomelli, Fabrice ^a   Mievis, Frederic ^a   Mestdagh, Nathalie ^b   Buchanan, Tim ^b   Valade, Anne ^b   Mercier, Joël ^b   Wood, Martyn ^b   Gillard, Michel ^b   Seret, Alain ^a   Luxen, André ^a   Salmon, Eric ^a   Plenevaux, Alain ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UCB PHARMA   (Belgium)

Author keywords

Brain imaging; Micropet; SV2A

Indexed keywords

ETIRACETAM; FLUORINE UCB H F 18; PEPTIDES AND PROTEINS; SYNAPTIC VESICLE PROTEIN 2A; TRACER; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; MEMBRANE PROTEIN; NERVE PROTEIN; PYRIDINE DERIVATIVE; SV2A PROTEIN, HUMAN; SV2A PROTEIN, RAT; UCB-H COMPOUND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG UPTAKE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIGAND BINDING; MALE; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; ANIMAL; BRAIN; DIAGNOSTIC USE; METABOLISM; SCINTISCANNING;

ANIMALS; BRAIN; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; PYRROLIDINONES; RADIOACTIVE TRACERS; RATS;

EID: 84905450170     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.136143     Document Type: Article

References (28)

1. Jahn R, Fasshauer D. Molecular machines governing exocytosis of synaptic vesicles. Nature. 2012;490:201-207.
2. Janz R, Sudhof TC, Hammer RE, Unni V, Siegelbaum SA, Bolshakov VY. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron. 1999;24:687-700.
3. Buckley K, Kelly RB. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol. 1985;100:1284-1294.
4. Crevecoeur J, Kaminski RM, Rogister B, et al. Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis. Neuropathol Appl Neurobiol. 2014;40:191-204.
5. Nowack A, Yao J, Custer KL, Bajjalieh SM. SV2 regulates neurotransmitter release via multiple mechanisms. Am J Physiol Cell Physiol. 2010;299:C960-C967.
6. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861-9866.
7. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994;14:5223-5235.
8. Janz R, Sudhof TC. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience. 1999;94:1279-1290.
9. +regulators in neurotransmitter release. Neuron. 1999;24:1003-1016.
10. Mercier J, Archen L, Bollu V, et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem. 2014;9:693-698.
11. 18F]UCB-H. EJNMMI Res. 2013;3:35.
12. Warnock G, Bahri MA, Goblet D, et al. Use of a beta microprobe system to measure arterial input function in PET via an arteriovenous shunt in rats. EJNMMI Res. 2011;1:13.
13. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
14. 3H]ucb 30889 to levetiracetam binding sites in rat brain. Eur J Pharmacol. 2003;478:1-9.
15. Motulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol. 1984;25:1-9.
16. 18F] fluoride for aliphatic and aromatic nucleophilic radiolabelling. Tetrahedron Lett. 2010;51:64-66.
17. 18F]UCB-H, a new fluorine-18 labelled tracer targeting synaptic vesicle protein 2A (SV2A): EANM Abstracts 2013. Eur J Nucl Med Mol Imaging. 2013;40:S89-S565.
18. Bahri MA, Plenevaux A, Warnock G, Luxen A, Seret A. NEMA NU4-2008 image quality performance report for the microPET Focus 120 and for various transmission and reconstruction methods. J Nucl Med. 2009;50:1730-1738.
19. Weber B, Späth N, Wyss M, et al. Quantitative cerebral blood flow measurements in the rat using a beta-probe and H2 15O. J Cereb Blood Flow Metab. 2003;23:1455-1460.
20. Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664:36-44.
21. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
22. 3H]citalopram binding to serotonin transporter sites in minnow brains. Basic Clin Pharmacol Toxicol. 2007;101:203-210.
23. Tanibuchi Y, Wu J, Toyohara J, Fujita Y, Iyo M, Hashimoto K. Characterization of [3H]CHIBA-1001 binding to alpha7 nicotinic acetylcholine receptors in the brain from rat, monkey, and human. Brain Res. 2010;1348:200-208.
24. Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA. 1999;96:15268-15273.
25. Morgans CW, Kensel-Hammes P, Hurley JB, et al. Loss of the synaptic vesicle protein SV2B results in reduced neurotransmission and altered synaptic vesicle protein expression in the retina. PLoS ONE. 2009;4:e5230.
26. Padurariu M, Ciobica A, Mavroudis I, Fotiou D, Baloyannis S. Hippocampal neuronal loss in the CA1 and CA3 areas of Alzheimer's disease patients. Psychiatr Danub. 2012;24:152-158.
27. Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci. 2003;23:2557-2563.
28. Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006213.